The scar neovasculature after myocardial infarction in rats

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 289, Issue 1 58-1, 2005, Pages

  Wang, Bin ^a,b   Ansari, Ramin ^a,b   Sun, Yao ^c   Postlethwaite, Arnold E ^c   Weber, Karl T ^c   Kiani, Mohammad F ^a,b,c,d  

^a Temple University   (United States)

^b TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^d NONE   (United States)

Author keywords

Hypoxic marker; Microcirculation; Myocardial infarction; Perfusion

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; CD31 ANTIGEN; LOSARTAN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE REPERFUSION; HEART VENTRICLE REMODELING; HYPOXEMIA; IMMUNOHISTOCHEMISTRY; MALE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; OXYGEN TRANSPORT; PRIORITY JOURNAL; RAT; RECEPTOR INTRINSIC ACTIVITY; RECEPTOR UPREGULATION; SCAR FORMATION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; CICATRIX; LOSARTAN; MALE; MYOCARDIAL INFARCTION; NEOVASCULARIZATION, PATHOLOGIC; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ANGIOTENSIN, TYPE 1; REGIONAL BLOOD FLOW;

EID: 21644442680     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpheart.00001.2005     Document Type: Article

References (39)

1. Agata J, Chao L, and Chao J. Kallikrein gene delivery improves cardiac reserve and attenuates remodeling after myocardial infarction. Hypertension 40: 653-659, 2002.
2. Anversa P, Olivetti G, and Capasso JM. Cellular basis of ventricular remodeling after myocardial infarction. Am J Cardiol 68: 7D-16D, 1991.
3. Cleutjens JP, Blankesteijn WM, Daemen MJ, and Smits JF. The infarcted myocardium: simply dead tissue, or a lively target for therapeutic interventions. Cardiovasc Res 44: 232-241, 1999.
4. Cleutjens JP, Kandala JC, Guarda E, Guntaka RV, and Weber KT. Regulation of collagen degradation in the rat myocardium after infarction. J Mol Cell Cardiol 27: 1281-1292, 1995.
5. Cox MM, Herman I, Myerburg RJ, Smets MJ, and Kozlovskis PL. Morphometric mapping of regional myocyte diameters after healing of myocardial infarction in cats. J Mol Cell Cardiol 23: 127-135, 1991.
6. Davani S, Marandin A, Mersin N, Royer B, Kantelip B, Herve P, Etievent JP, and Kantelip JP. Mesenchymal progenitor cells differentiate into an endothelial phenotype, enhance vascular density, and improve heart function in a rat cellular cardiomyoplasty model. Circulation 108, Suppl 1: II253-II258, 2003.
7. De Boer RA, Pinto YM, Suurmeijer AJ, Pokharel S, Schottens E, Humler M, Saavedra JM, Boomsma F, van Gilst WH, and van Veldhuisen DJ. Increased expression of cardiac angiotensin II type 1 [AT(1)] receptors decreases myocardial microvessel density after experimental myocardial infarction. Cardiovasc Res 57: 434-442, 2003.
8. Evers BM, Weissman IL, Flake AW, Tabar V, and Weisel RD. Stem cells in clinical practice. J Am Coll Surg 197: 458-478, 2003.
9. Fenton BM. Influence of hydralazine administration on oxygenation in spontaneous and transplanted tumor models. Int J Radiat Oncol Biol Phys 49: 799-808, 2001.
10. Fenton BM, Paoni SF, Beauchamp BK, and Ding I. Zonal image analysis of tumour vascular perfusion, hypoxia, and necrosis. Br J Cancer 86: 1831-1836, 2002.
11. 2 saturation measurements. Br J Cancer 79: 464-471, 1999.
12. Ji X, Tan BK, Zhu YC, Linz W, and Zhu YZ. Comparison of cardioprotective effects using ramipril and DanShen for the treatment of acute myocardial infarction in rats. Life Sci 73: 1413-1426, 2003.
13. Kalkman EA, van Haren P, Saxena PR, and Schoemaker RG. Regionally different vascular response to vasoactive substances in the remodelled infarcted rat heart; aberrant vasculature in the infarct scar. J Mol Cell Cardiol 29: 1487-1497, 1997.
14. Khaper N and Singal PK. Modulation of oxidative stress by a selective inhibition of angiotensin II type 1 receptors in MI rats. J Am Coll Cardiol 37: 1461-1466, 2001.
15. Koch CJ. Measurement of absolute oxygen levels in cells and tissues using oxygen sensors and 2-nitroimidazole EF5. Methods Enzymol 352: 3-31, 2002.
16. Koch CJ, Evans SM, and Lord EM. Oxygen dependence of cellular uptake of EF5 [2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)a cet amide]: analysis of drug adducts by fluorescent antibodies vs. bound radioactivity. Br J Cancer 72: 869-874, 1995.
17. Lefroy DC, Wharton J, Crake T, Knock GA, Rutherford RA, Suzuki T, Morgan K, Polak JM, and Poole-Wilson PA. Regional changes in angiotensin II receptor density after experimental myocardial infarction. J Mol Cell Cardiol 28: 429-440, 1996.
18. Levine SA. Coronary thrombosis: its various clinical features. Medicine 8: 245-418, 1929.
19. Lodge-Patch I. The ageing of cardiac infarcts, and its influence on cardiac rupture. Br Heart J 13: 37-42, 1951.
20. Lord EM, Harwell L, and Koch CJ. Detection of hypoxic cells by monoclonal antibody recognizing 2-nitroimidazole adducts. Cancer Res 53: 5721-5726, 1993.
21. Lu L, Quinn MT, and Sun Y. Oxidative stress in the infarcted heart: role of de novo angiotensin II production. Biochem Biophys Res Commun 325: 943-951, 2004.
22. Maity A, Sail W, Koch CJ, Oprysko PR, and Evans SM. Low pO2 and beta-estradiol induce VEGF in MCF-7 and MCF-7-5C cells: relationship to in vivo hypoxia. Breast Cancer Res Treat 67: 51-60, 2001.
23. Mallory GK, White PD, and Salcedo-Salgar J. The speed of healing of myocardial infarction: a study of the pathologic anatomy in seventy-two cases. Am Heart J 18: 647-671, 1939.
24. Mehrabi MR, Serbecic N, Tamaddon F, Pacher R, Horvath R, Mall G, and Glogar HD. Clinical benefit of prostaglandin E1-treatment of patients with ischemic heart disease: stimulation of therapeutic angiogenesis in vital and infarcted myocardium. Biomed Pharmacother 57: 173-178, 2003.
25. Olivetti G, Ricci R, Beghi C, Guideri G, and Anversa P. Response of the border zone to myocardial infarction in rats. Am J Pathol 125: 476-483, 1986.
26. Rubin SA, Fishbein MC, and Swan HJ. Compensatory hypertrophy in the heart after myocardial infarction in the rat. J Am Coll Cardiol 1: 1435-1441, 1983.
27. 1 receptor antagonist on chronic cardiac response to coronary artery ligation in rats. Cardiovasc Res 31: 568-576, 1996.
28. Sugimoto T, Inui K, and Shimazaki Y. Gene therapy for myocardial angiogenesis: with direct intramuscular gene transfer of naked deoxyribonucleic acid encoding vascular endothelial growth factor and cell transplantation of vascular endothelial growth factor transfected H9c2 myoblast. Jpn J Thorac Cardiovasc Surg 51: 192-197, 2003.
29. Sun Y, Cleutjens JP, Diaz-Arias AA, and Weber KT. Cardiac angiotensin converting enzyme and myocardial fibrosis in the rat. Cardiovasc Res 28: 1423-1432, 1994.
30. Sun Y, Kiani MF, Postlethwaite AE, and Weber KT. Infarct scar as living tissue. Basic Res Cardiol 97: 343-347, 2002.
31. Sun Y and Weber KT. Angiotensin II receptor binding following myocardial infarction in the rat. Cardiovasc Res 28: 1623-1628, 1994.
32. Sun Y and Weber KT. Angiotensin converting enzyme and myofibroblasts during tissue repair in the rat heart. J Mol Cell Cardiol 28: 851-858, 1996.
33. Sun Y and Weber KT. Infarct scar: a dynamic tissue. Cardiovasc Res 46: 250-256, 2000.
34. Sun Y, Zhang J, Zhang JQ, and Weber KT. Renin expression at sites of repair in the infarcted rat heart. J Mol Cell Cardiol 33: 995-1003, 2001.
35. Sun Y, Zhang JQ, Zhang J, and Ramires FJ. Angiotensin II, transforming growth factor-beta1 and repair in the infarcted heart. J Mol Cell Cardiol 30: 1559-1569, 1998.
36. Tomanek RJ. Response of the coronary vasculature to myocardial hypertrophy. J Am Coll Cardiol 15: 528-533, 1990.
37. Trochu JN, Bouhour JB, Kaley G, and Hintze TH. Role of endothelium-derived nitric oxide in the regulation of cardiac oxygen metabolism: implications in health and disease. Circ Res 87: 1108-1117, 2000.
38. Tzanidis A, Lim S, Hannan RD, See F, Ugoni AM, and Krum H. Combined angiotensin and endothelin receptor blockade attenuates adverse cardiac remodeling post-myocardial infarction in the rat: possible role of transforming growth factor beta(1). J Mol Cell Cardiol 33: 969-981, 2001.
39. Weber KT, Gerling IC, Kiani MF, Guntaka RV, Sun Y, Ahokas RA, Postlethwaite AE, and Warrington KJ. Aldosteronism in heart failure: a proinflammatory/fibrogenic cardiac phenotype. Search for biomarkers and potential drug targets. Curr Drug Targets 4: 505-516, 2003.